Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Criopulverización dosificada para el tratamiento de pacientes con enfermedad pulmonar obstructiva crónica con bronquitis crónica

25 de septiembre de 2026 actualizado por: CSA Medical, Inc.

Caracterización del mecanismo de acción del criopulverizador dosificado para el tratamiento de pacientes con enfermedad pulmonar obstructiva crónica con bronquitis crónica

To evaluate the relationship between airway structure and function in patients with chronic bronchitis treated with metered cryospray (MCS).

Descripción general del estudio

Estado

Terminado

Descripción detallada

To identify the molecular and cellular targets of MCS treatment and determine the mechanistic relationship to airways remodelling in patients with chronic bronchitis. Phenotype, characterise and correlate clinical, physiological, histological and molecular parameters in patients with chronic bronchitis.

Tipo de estudio

Intervencionista

Inscripción (Actual)

32

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Groningen, Países Bajos
        • University Medical Center Groningen
      • London, Reino Unido, SW3 6NP
        • The Royal Brompton Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 79 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Each Subject must meet the following criteria to be enrolled in the study:

  1. Males and females ≥40 to <80 years of age.
  2. Subject is able to read, understand, and sign a written Informed Consent in order to participate in the study.
  3. Subject has a diagnosis of CB and COPD and has been symptomatic for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded).
  4. Subject is classified as having moderate or severe (GOLD stage 2-3) airflow obstruction defined by a post-bronchodilator of =>30% FEV1 to <80% predicted with a baseline FEV1/FVC of <0.70.
  5. Subject has a COPD assessment tool (CAT) score of ≥10.
  6. Subject is being treated according to current medically accepted treatment guidelines without successful resolution of chronic bronchitis and agrees to continue maintenance pulmonary/COPD medications (as defined per GOLD Standard for medications) for the duration of the study (subject must be on a regime of pulmonary medications for a minimum of 2 weeks prior to enrolment into the study).
  7. Smoking history of at least 10 pack years.
  8. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study.
  9. Subject is able to adhere to and undergo 4 bronchoscopic procedures (5 for control subjects accepting cross over option), in the opinion of the investigator or per hospital guidelines.
  10. For women of childbearing potential: non-pregnant, non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 6 weeks of initially planned study bronchoscopy.
  2. Diagnosis of asthma with an onset before 30 years of age.
  3. Subject has Alpha-1 antitrypsin deficiency.
  4. Subject has other origins of respiratory disease aside from chronic bronchitis and COPD.
  5. Subject is using e-cigarettes, vaping or taking any oral or inhaled substances not prescribed by a physician.
  6. Subject has untreatable or life-threatening arrhythmias, or history of inability to adequately oxygenate during a bronchoscopy, or has acute respiratory failure with hypercapnia.
  7. Subject has bullous emphysema characterized as large bullae >30 millimetres on HRCT; or subject has stenosis in the tracheobronchial system, tracheobronchomegaly, trachea-bronchomalacia, amyloidosis or cystic fibrosis.
  8. Subject has clinically significant bronchiectasis
  9. Subject has had a transplant procedure (any).
  10. Subject has a known mucosal tear, has undergone prior lung surgery such as pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery, bronchial thermoplasty, rheoplasty or cryotherapy.
  11. Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation or other devices for emphysema.
  12. Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal).
  13. Subject has a serious medical condition, such as: uncontrolled coagulopathy or bleeding disorder, congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension, autoimmune disease or uncontrolled gastric reflux.
  14. Subject has or is receiving chemotherapy or active radiation therapy within the past 6 months or is expected to receive chemotherapy during participation in this study.
  15. Subject is or has been in another clinical investigational study within 6 weeks of enrolment.
  16. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Treatment

MCS

Bronchial metered cryospray using RejuvenAir® System.

Comparador falso: Sham Control

Sham

Sham control procedure

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Goblet cell density
Periodo de tiempo: 6-months post treatment

Difference in change relative to baseline in goblet cell density per mm of basement membrane in endobronchial cryobiopsies at 6-months between treatment and sham-control groups

6-months post treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Histopathological examination of endobronchial cryobiopsies to determine Inflammatory cells and subtype density per mm of basement membrane
Periodo de tiempo: 6-months post treatment

Proportion of inflammatory cells per mm of basement membrane for Neutrophil and Lymphocyte sequencing (RNA-seq)

6-months post treatment
Histopathological examination of endobronchial cryobiopsies to determine epithelial cell density and area (including respiratory epithelial, goblet and basal cells) per mm of basement membrane
Periodo de tiempo: 6-months post treatment

Proportion of epithelial cells per mm of basement membrane for Ciliary and Goblet cells

6-months post treatment
Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq)
Periodo de tiempo: 6-months post treatment

Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq)

6-months post treatment
Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO
Periodo de tiempo: 6-months post treatment

Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO

6-months post treatment
Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires
Periodo de tiempo: 6-months post treatment

Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires

6-months post treatment
Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events
Periodo de tiempo: 6-months post treatment

Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events

6-months post treatment
The 6-minute walk tests
Periodo de tiempo: 6-months post treatment

The 6-minute walk tests

6-months post treatment

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Microvesicle quantification
Periodo de tiempo: 6-months post treatment

Microvesicle quantification

6-months post treatment
Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping
Periodo de tiempo: 6-months post treatment

Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping

6-months post treatment
Small airways function as assessed by Impulse Oscillometry (IOS)
Periodo de tiempo: 6-months post treatment

Small airways function as assessed by Impulse Oscillometry (IOS)

6-months post treatment
Composition of epithelial ultrastructure as assessed by transmission electron microscopy
Periodo de tiempo: 6-months post treatment

Composition of epithelial ultrastructure as assessed by transmission electron microscopy

6-months post treatment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Pallav Shah, MD, The Royal Brompton Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de febrero de 2020

Finalización primaria (Actual)

11 de julio de 2022

Finalización del estudio (Actual)

12 de diciembre de 2022

Fechas de registro del estudio

Enviado por primera vez

26 de marzo de 2019

Primero enviado que cumplió con los criterios de control de calidad

26 de marzo de 2019

Publicado por primera vez (Actual)

27 de marzo de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir